BioCentury
ARTICLE | Product Development

Challenging psoriasis biologics

August 21, 2006 7:00 AM UTC

Leo Pharma A/S is hoping that a recently published meta-analysis comparing its Daivobet ointment for severe psoriasis to Enbrel etanercept, Raptiva efalizumab and Amevive alefacept will make it easier to sell its product. This is also the first time that data have been published showing how many psoriasis patients receiving Daivobet achieved PASI 50 and PASI 75 scores.

With those data now available, the company hopes patients and doctors will prefer its inexpensive topical over the more expensive injectable biologics...